Overview

Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients

Status:
Not yet recruiting

Trial end date:
2024-10-19

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determin whether HIF-PHI is safe and effective in the treatment of anemia and meanwhile reduces the risk of cardiovascular and cerebrovascular events in patients who have just initiated dialysis.

Phase:

Phase 4

Details

Lead Sponsor:

Second Xiangya Hospital of Central South University

Treatments:

Epoetin Alfa